Beijing Sun-Novo Pharmaceutical Research Third Quarter 2024 Earnings: EPS: CN¥0.52 (vs CN¥0.48 in 3Q 2023)

Beijing Sun-Novo Pharmaceutical Research (SHSE:688621) Third Quarter 2024 Results

Key Financial Results

• Revenue: CN¥353.8m (up 53% from 3Q 2023).
• Net income: CN¥59.1m (up 11% from 3Q 2023).
• Profit margin: 17% (down from 23% in 3Q 2023). The decrease in margin was driven by higher expenses.
• EPS: CN¥0.52 (up from CN¥0.48 in 3Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Beijing Sun-Novo Pharmaceutical Research Earnings Insights

Looking ahead, revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Life Sciences industry in China.

Performance of the Chinese Life Sciences industry.

The company's shares are up 1.9% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 1 warning sign for Beijing Sun-Novo Pharmaceutical Research that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.